|プログラムへの申請

Screening Platform

Current Open RFP

GHIT Fund RFP Screening Platform 2017-002

The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions. 

 

The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.

 

Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).

 

GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding. 


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

September 1, 2017

Intent to Apply

N/A

Q&A

Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2017-002 Contact Form"

Full Proposal Due

Submit GHIT RFP Screening Platform 2017-002 Contact Form to RFPResponse@ghitfund.org

Email Subject Line: Potential Screening Platform 2017-002

Award Notification to All Applicants

To be announced to awarded applicants

Past RFP

GHIT Fund RFP Screening Platform 2017-001

The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions. 

 

The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.

 

Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).

 

GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding. 


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

April 1, 2017

Intent to Apply

N/A

Q&A

Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2017-001 Contact Form

Full Proposal Due

Submit GHIT RFP Screening Platform 2017-001 Contact Form to RFPResponse@ghitfund.org

Email Subject Line: Potential Screening Platform 2017-001

Award Notification to All Applicants

To be announced to awarded applicants

GHIT Fund RFP Screening Platform 2016-002

The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions. 

 

The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.

 

Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).

 

GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding. 


RFP and Intent to Apply

Key RFP Milestone Dates

Intent to Apply

N/A

Q&A

Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2016-002 Contact Form

Full Proposal Due

Submit GHIT RFP Screening Plartform 2016-002 Contact Form to RFPResponse@ghitfund.org

Email Subject Line: Potential Screening Platform 2016-002

Award Notification to All Applicants

To be announced to awarded applicants

GHIT Fund RFP Screening Platform 2016-001

The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions. 

 

The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.

 

Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).

 

GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding. 


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

March 11, 2016

Intent to Apply

N/A

Q&A

Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2016-001 Contact Form

Full Proposal Due

Submit GHIT RFP Screening Plartform 2016-001 Contact Form to RFPResponse@ghitfund.org

Email Subject Line: Potential Screening Platform 2016-001

Award Notification to All Applicants

To be announced to awarded applicants

GHIT Fund RFP Screening Platform 2015-002

The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions. 

 

The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.

 

Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).

 

GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding. 


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

September 1, 2015

Intent to Apply

N/A

Q&A

Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2015-002 Contact Form

Full Proposal Due

Submit GHIT RFP Screening Plartform 2015-002 Contact Form to RFPResponse@ghitfund.org

Email Subject Line: Potential Screening Platform 2015-002

Award Notification to All Applicants

To be announced to awarded applicants.

GHIT Fund RFP Screening Platform 2015-001

The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions. 

 

The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.

 

Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).

 

GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding. 


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

March 25, 2015

Intent to Apply

N/A

Q&A

Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2015-001 Contact Form".

Full Proposal Due

Submit GHIT RFP Screening Plartform 2015-001 Contact Form to RFPResponse@ghitfund.org

Email Subject Line: Potential Screening Platform 2015-001

Award Notification to All Applicants

To be announced to awarded applicants.

GHIT Fund RFP Screening Platform 2014-002

The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions. 

 

The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.

 

Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).

 

GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding. 


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

September 1, 2014

Intent to Apply

N/A

Q&A

Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2014-002 Contact Form".

Full Proposal Due

Submit GHIT RFP Screening Plartform 2014-002 Contact Form to RFPResponse@ghitfund.org

Email Subject Line: Potential Screening Platform 2014-002

Award Notification to All Applicants

To be announced to awarded applicants.

GHIT Fund RFP Screening Platform 2014-001

The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions. 

 

The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.

 

Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).

 

GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding. 


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

May 22, 2014

Intent to Apply

N/A

Q&A

Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2014-001 Contact Form".

Full Proposal Due

Submit GHIT RFP Screening Plartform 2014-001 Contact Form to RFPResponse@ghitfund.org

Email Subject Line: Potential Screening Platform 2014-001

Award Notification to All Applicants

To be announced to awarded applicants.

GHIT Fund RFP Screening Platform 2013-002

The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions.

The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.

Possible collaborations should include three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).

Interested partnerships are required to submit the Contact Form by email to RFPResponse@ghitfund.org no later than 5:00pm JST on January 31th, 2014 (please use email subject: Potential Screening Platform 2013-002). Questions specific to this Screening Platform can only be answered with the submission of this information.

A GHIT Fund staff member will contact interested parties to discuss the funding process. If partnerships have not been identified, GHIT Fund staff are available to help facilitate communication with prospective parties. Interested organizations that are not able to form a partnership by the above deadline will be encouraged to participate in future funding calls.


RFP and Intent to Apply

GHIT Fund RFP Screening Platform 2013-001

The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions. The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs. Possible collaborations should include three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).


RFP and Intent to Apply

RFP Schedule

GHIT Fund RFP Schedule of Screening Platform

2018-001

RFP ReleaseApr, 2018

|製品開発投資のプロセス

process1

申請者

Contact Formの提出

公募案件(RFP)へ申請を希望する機関は、Contact Form必要事項を記入し、RFPResponse@ghitfund.org宛にメールで提出する必要があります。

process2

GHIT Fundマネジメントチーム

事前審査

GHITマネジメントチームが、パートナーシップ、疾患、製品、開発ステージの観点から事前審査を行います。

process3

申請者

プロジェクトスコープについてPDPと協議

申請の条件として、日本国内の機関と、Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases initiative (DNDi), and the Global Alliance for TB Drug Development (GATB)のいずれかのProduct Development Partnerships (PDPs)がパートナーシップを組んでいる必要があります。スクリーニング事業の詳細については、各PDPの代表者と協議します。

process4

理事会

評価

理事会のメンバーが各スクリーニング計画を評価します。

process5

日本の機関 & PDPs & GHIT Fund

契約締結

承認されたスクリーニング案件は、三者間(日本の機関、PDPs、GHIT Fund)で契約を締結した後、スクリーニング事業を開始します。

process6

GHIT Fundマネジメントチーム

モニタリングと評価の開始

契約を締結しプロジェクトが開始すると、GHITマネジメントチームはモニタリングと評価を開始します。プロジェクトに関するデータと情報がシステム上で管理されます。

process7

GHIT Fundマネジメントチーム&製品開発パートナー

モニタリングと評価

投資案件の進捗状況を把握するため、GHIT Fundは年に2回、全ての投資案件の進捗確認を実施します。これにより、各案件におけるマイルストーンの達成度を確認し、投資の継続、変更、または終了の決定を行います。このモニタリングと評価を通じて、製品開発パートナーはウェブサイト上のシステムを用いて進捗報告を提出し、その報告をもとに、GHIT Fundマネジメントチームとの会議を行います。